A request by the Food and Drug Administration that Sarepta Therapeutics provide for more data before Phase 3 trials start on a Duchenne muscular dystrophy treatment sent SRPT stock falling.

The post Sarepta Therapeutics Stock Falls On Delay In Quest For Muscular Dystrophy Treatment appeared first on Investor's Business Daily.